The FY26 Peer Reviewed Cancer Research Program Clinical Trial Award supports rapid implementation of clinical trials that can significantly impact cancer treatment or management. Eligible trials range from small proof-of-concept to large phase III studies, evaluating new drugs, devices, clinical guidance, or emerging technologies. Applications must include patient advocates and regulatory submissions if required. Animal studies are excluded; all preclinical work must be completed before award start.
Open to any type of entity, with no specific restrictions stated. Applications must include patient advocates and preclinical work must be completed before award start.
